FITC-Labeled Human CLEC12A / MICL / CLL-1 Protein, His Tag
分子別名（Synonym）
CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
FITC-Labeled Human CLEC12A, His Tag (CLA-HF247) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2). It is the FITC labeled form of Human CLEC12A, His Tag (CLA-H5245).
Predicted N-terminus: His
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 25.6 kDa. The protein migrates as 35-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
標(biāo)記（Labeling）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
蛋白標(biāo)記度（FITC:Protein Ratio)
The FITC to protein molar ratio is 2-4.5.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
CLEC12A（C型凝集素結(jié)構(gòu)域家族12成員A）也稱為CLL1、DCAL2、MICL。Clec12a是尿酸晶體的抑制性受體，在細(xì)胞死亡時調(diào)節(jié)炎癥。調(diào)節(jié)信號級聯(lián)并介導(dǎo)靶MAP激酶酪氨酸磷酸化的細(xì)胞表面受體。近年來，骨髓增生異常綜合征（MDS）中出現(xiàn)了不同疾病增殖干細(xì)胞的證據(jù)。然而，CLEC12A在MDS中的作用仍有待闡明。此外，CLEC12A已被提出作為AML中白血病干細(xì)胞的有前景的標(biāo)志物。
關(guān)鍵字： CLEC12A;CLEC12A蛋白;CLEC12A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。